Trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease

Recruiting
99 years or below
All
Phase N/A
5 participants needed
1 Location

Brief description of study

The main purpose of this study is to see if study drug CAM2029 works and is safe for people with polycystic liver disease (PLD). The study will also look at: 
• How the study drug affects the body (“pharmacodynamics”) 
• What the body does to the study drug (“pharmacokinetics”). 
This is a Phase 2/3 study, and the study drug has already been tested in a small group of participants with other conditions than PLD. If you decide to join the study, your total time in the study will be about 20 months. The study includes the following periods: 
• Screening period (up to 4 weeks) 
• Study treatment period (52 weeks, about 12 months) 
• Extension period (24 weeks, about 6 months) 
• Follow-up period (4 weeks, about 1 month)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Polycystic Liver Disease
  • Age: 99 years or below
  • Gender: All


Updated on 04 Aug 2024. Study ID: 850865

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center